NÃºria Plana

List of Publications by Year
in descending order

56 papers	1,451 citations	304743 22 h-index	361022 35 g-index
61 all docs	61 docs citations	61 times ranked	1952 citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 157-164.	3.0	64
2	Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation. Atherosclerosis, 2022, 349, 211-218.	0.8	12
3	Patrón de metilación en ADN de sujetos hipertrigliceridémicos. Clínica E Investigación En Arteriosclerosis, 2022, 34, 27-32.	0.8	2
4	El rastreo masivo de datos es una segunda oportunidad para mejorar el manejo de los pacientes fenotipo de hipercolesterolemia familiar. Clínica E Investigación En Arteriosclerosis, 2021, 33, 138-147.	0.8	1
5	Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia. Atherosclerosis, 2021, 320, 47-52.	0.8	7
6	Low HDL and high triglycerides predict COVID-19 severity. Scientific Reports, 2021, 11, 7217.	3.3	122
7	Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype. Clínica E Investigación En Arteriosclerosis (English Edition), 2021, 33, 138-147.	0.2	2
8	Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1594-1603.	2.6	9
9	Serum glycoproteins A and B assessed by 1H-NMR in familial hypercholesterolemia. Atherosclerosis, 2021, 330, 1-7.	0.8	9
10	Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease. Frontiers in Endocrinology, 2021, 12, 775677.	3.5	4
11	Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk. Frontiers in Physiology, 2021, 12, 781789.	2.8	5
12	Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype. Atherosclerosis, 2020, 292, 42-51.	0.8	9
13	Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes. Revista Espanola De Cardiologia (English Ed), 2020, 73, 718-724.	0.6	6
14	Polygenic Markers in Patients Diagnosed of Autosomal Dominant Hypercholesterolemia in Catalonia: Distribution of Weighted LDL-c-Raising SNP Scores and Refinement of Variant Selection. Biomedicines, 2020, 8, 353.	3.2	6
15	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets. Current Cardiology Reports, 2020, 22, 66.	2.9	26
16	Diferencias clínicas y genéticas de los pacientes con hipercolesterolemia familiar heterocigota con y sin diabetes mellitus tipo 2. Revista Espanola De Cardiologia, 2020, 73, 718-724.	1.2	11
17	Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia. Clínica E Investigación En Arteriosclerosis, 2020, 32, 49-58.	0.8	3
18	Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients. Journal of Clinical Medicine, 2019, 8, 1080.	2.4	33

#	Article	IF	Citations
19	HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk. International Journal of Molecular Sciences, 2019, 20, 3151.	4.1	58
20	Estándares SEA 2019 para el control global del riesgo cardiovascular. Clínica E Investigación En Arteriosclerosis, 2019, 31, 1-43.	0.8	8
21	The Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing Endoplasmic Reticulum Stress into the Clinical Scenario. Journal of Clinical Medicine, 2019, 8, 1793.	2.4	40
22	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. Atherosclerosis, 2019, 287, 89-92.	0.8	29
23	Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors. Response. Revista Espanola De Cardiologia (English Ed), 2019, 72, 519-520.	0.6	1
24	Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. Atherosclerosis, 2019, 284, 245-252.	0.8	55
25	Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. Lipids in Health and Disease, 2019, 18, 216.	3.0	16
26	Actualización de las tablas de planificación terapéutica hipocolesterolemiante orientadas a la obtención de los objetivos terapéuticos. Clínica E Investigación En Arteriosclerosis, 2019, 31, 271-277.	0.8	13
27	Valor de los parámetros lipídicos y apoproteicos para la detección de hipercolesterolemia familiar en la infancia. Proyecto DECOPIN. Clínica E Investigación En Arteriosclerosis, 2018, 30, 170-178.	0.8	9
28	Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients. Revista Espanola De Cardiologia (English Ed), 2018, 71, 1010-1017.	0.6	10
29	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels—The zero-LDL hypothesis. Journal of Clinical Lipidology, 2018, 12, 292-299.e3.	1.5	51
30	Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia. Atherosclerosis, 2018, 270, 117-122.	0.8	11
31	Número de pacientes candidatos a recibir inhibidores de la PCSK9 según datos de 2,5 millones de participantes de la práctica clínica real. Revista Espanola De Cardiologia, 2018, 71, 1010-1017.	1.2	23
32	Causas de no consecución del objetivo terapéutico del colesterol de las lipoproteínas de baja densidad en pacientes de alto y muy alto riesgo vascular controlados en Unidades de Lípidos y Riesgo Vascular. Estudio EROMOT. Clínica E Investigación En Arteriosclerosis, 2018, 30, 1-9.	0.8	8
33	Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. Journal of Clinical Lipidology, 2018, 12, 211-218.	1.5	14
34	Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting. Journal of Clinical Lipidology, 2018, 12, 1452-1462.	1.5	14
35	Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:The DECOPIN project. Atherosclerosis, 2018, 278, 210-216.	0.8	18
36	Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients. American Journal of Cardiology, 2017, 119, 742-748.	1.6	17

#	Article	IF	Citations
37	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. Atherosclerosis, 2017, 262, 107-112.	0.8	22
38	Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients. Journal of Clinical Lipidology, 2017, 11, 1013-1022.	1.5	61
39	Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia. Scientific Reports, 2017, 7, 5596.	3.3	41
40	Hipercolesterolemia familiar en la infancia y la adolescencia: una realidad oculta. Clínica E Investigación En Arteriosclerosis, 2017, 29, 129-140.	0.8	8
41	Registro Nacional de Dislipemias de la Sociedad Española de Arteriosclerosis: situación actual. Clínica E Investigación En Arteriosclerosis, 2017, 29, 248-253.	0.8	20
42	Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes. Scientific Reports, 2016, 6, 19249.	3.3	25
43	Máxima reducción de colesterol unido a lipoproteínas de baja densidad alcanzable con combinaciones farmacológicas. Cuando 50 más 20 suma 60. Revista Espanola De Cardiologia, 2016, 69, 342-343.	1.2	24
44	Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. Cardiovascular Diabetology, 2016, 15, 107.	6.8	28
45	Impact of epidermal fatty acid binding protein on 2D-NMR—assessed atherogenic dyslipidemia and related disorders. Journal of Clinical Lipidology, 2016, 10, 330-338.e2.	1.5	9
46	Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. Clínica E Investigación En Arteriosclerosis, 2016, 28, 71-78.	0.8	35
47	Novel mutations in the GPIHBP1 gene identified in 2 patients with recurrent acute pancreatitis. Journal of Clinical Lipidology, 2016, 10, 92-100.e1.	1.5	27
48	Letter to Editor: Increased Presence of Remnant Lipoprotein Cholesterol in The Hdl of Diabetic Subjects. Annals of Clinical and Laboratory Science, 2016, 46, 229-32.	0.2	0
49	Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. Journal of Lipid Research, 2015, 56, 737-746.	4.2	133
50	APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. Atherosclerosis, 2015, 240, 98-104.	0.8	28
51	Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis, 2015, 238, 213-219.	0.8	23
52	Low-carbohydrate, high-protein, high-fat diet alters small peripheral artery reactivity in metabolic syndrome patients. Clínica E Investigación En Arteriosclerosis, 2014, 26, 58-65.	0.8	5
53	Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate—high cardiovascular risk. Journal of Nutritional Biochemistry, 2014, 25, 642-646.	4.2	19
54	Heterozygous Familial Hypercholesterolaemic Patients have Increased Arterial Stiffness, as Determined using the Augmentation Index. Journal of Atherosclerosis and Thrombosis, 2011, 18, 1110-1116.	2.0	18

#	Article	IF	Citations
55	Comparison of Genetic Versus Clinical Diagnosis in Familial Hypercholesterolemia. American Journal of Cardiology, 2008, 102, 1187-1193.e1.	1.6	153
56	Physicochemical changes in HDL3 after bezafibrate treatment: influence on free cholesterol efflux from human fibroblasts. Cardiovascular Drugs and Therapy, 1997, 11, 653-658.	2.6	7